Table 1.
Selected demographic and clinical data of main groups of anti-HBc positive HD patients.
| All anti-HBc positive HD patients (n=170) | |||
|---|---|---|---|
| Parameter | Anti-HBs positive (n=127) | Anti-HBs negative (n=43) | P value |
| Men, n (% of all) | 71 (55.9) | 28 (65.1) | 0.371a |
| Age, years | 61.6±14.4 | 59.3±15.5 | 0.391b |
| RRT duration, years | 2.8 (0.05–26.3) | 3.6 (0.05–25.1) | 0.139c |
| Causes of end-stage renal disease, n (% of all) | |||
| Diabetic nephropathy | 37 (29.1) | 11 (25.6) | 0.700a |
| Hypertensive nephropathy | 20 (15.7) | 6 (14.0) | 0.778d |
| Chronic glomerulonephritis | 18 (14.2) | 14 (32.6) | 0.008d |
| Chronic tubulointerstitial nephritis | 10 (7.9) | 3 (7.0) | 0.888e |
| Polycystic kidney disease | 7 (5.5) | 1 (2.3) | 0.663e |
| 346g, 1752g, 3691g, 1884g or other | 35 (27.6) | 8 (18.6) | 0.311a |
| ALT (U/L) | 16 (2–195) | 18 (4–53) | 0.446f |
| AST (U/L) | 18 (6–152) | 18 (6–81) | 0.651f |
| GGT (U/L) | 26 (4–498) | 25 (7–284) | 0.936f |
| Anti-HBs positive (n=127) | |||
| Parameter | Diabetics (n=37) | Non-diabetics (n=90) | P value |
| Men, n (% of all) | 18 (48.6) | 53 (58.9) | 0.329a |
| Age, years | 63.3±13.1 | 60.8±14.9 | 0.381b |
| RRT duration, years | 2.0 (0.05–15.7) | 3.4 (0.14–26.3) | 0.008c |
| Causes of end-stage renal disease, n (% of all) | |||
| Diabetic nephropathy | 37 (100) | 0 (0) | |
| Chronic glomerulonephritis | – | 18 (20.0) | – |
| Hypertensive nephropathy | – | 20 (22.2) | – |
| Chronic tubulointerstitial nephritis | – | 10 (11.1) | – |
| Polycystic kidney disease | – | 7 (7.8) | – |
| 346g, 1752g, 3691g, 1884g or other | – | 35 (38.9) | – |
| ALT (U/l) | 18 (2–195) | 14 (2–95) | 0.315f |
| AST (U/l) | 18 (9–152) | 17.5 (6–72) | 0.588f |
| GGT (U/l) | 25 (12–168) | 27 (4–498) | 0.944f |
| Anti-HBs negative (n=43) | |||
| Parameter | Diabetics (n=11) | Non-diabetics (n=32) | P value |
| Men, n (% of all) | 6 (54.5) | 22 (68.8) | 0.627e |
| Age, years | 64.7±12.4 | 57.5±16.2 | 0.189b |
| RRT duration, years | 3.6 (0.24–24.2) | 4.7 (0.05–25.1) | 0.770c |
| Causes of end-stage renal disease, n (% of all) | |||
| Diabetic nephropathy | 11 (100) | 0 (0) | |
| Chronic glomerulonephritis | – | 14 (43.8) | – |
| Hypertensive nephropathy | – | 6 (18.8) | – |
| Chronic tubulointerstitial nephritis | – | 3 (9.4) | – |
| Polycystic kidney disease | – | 1 (3.1) | – |
| 1752g, 2578g, 1832g, 1396g or other | – | 8 (25.0) | – |
| ALT (U/l) | 18 (8–45) | 17.5 (4–53) | 0.738f |
| AST (U/l) | 19 (11–81) | 17 (6–52) | 0.549f |
| GGT (U/l) | 23 (11–93) | 35 (7–284) | 0.684f |
ALT – alanine aminotransferase; anti-HBc – antibodies to core antigen of hepatitis B virus; anti-HBs – antibodies to surface antigen of hepatitis B virus; AST – aspartate aminotransferase; GGT – gamma-glutamyltranspeptidase; HD – hemodialysis; RRT – renal replacement therapy. Statistical tests:
a
– Chi square;
b
– t student;
c
– Mann Whitney;
d
– V square;
e
– Yates corrected Chi-square;
f
– Mann Whitney;
g
– renal diagnosis codes for the ERA-EDTA [58].
Significant differences are indicated using bold font.